Multimedia

Robert Dupont, MD, discusses his session at the recent Rx Drug Abuse & Heroin Summit that educated virtual attendees about the need for a “peace plan” between the different addiction treatment programs and the “many paths to recovery”.

Jaime Vinck, MC, LPC, is back on the BHE Podcast to discuss her transition to a new role as CEO of CPF Recovery Ways, as well as the company’s recent expansion that included the addition of programs in Texas and Washington. Vinck explains her organization’s philosophy for identifying strategic partners, why she thinks private equity gets a bad rap, and how her experiences leading the growth of…

In this video, Dr. Todd Lencz discusses how his study that identified a rare gene mutation that could result in schizophrenia can apply to future treatment and studies and one day help to develop a prognostic biomarker.

In this Q&A, Dorothy Sit, MD, discusses the current clinical indications of bright light therapy, novel visual and neural biomarkers in patients with bipolar depression, and more from her upcoming APA session.

Karen Scott, MD, MPH, explains how the COVID‑19 pandemic affected access to treatment for opioid use disorder (OUD) and discusses policy changes that would allow maximum access to OUD treatment and recovery services.

Psych Congress Steering Committee member Rakesh Jain, MD, MPH, explains the similarities and differences between the 2 medications approved by the US Food and Drug Administration for the treatment of tardive dyskinesia.

Sleep Disorders Section Editor Karl Doghramji, MD, reviews the neurotransmitter systems governing sleep and wakefulness, the variety of prescription medications available for sleep difficulties, and agents that have recently been approved or are in development.

Sponsored by Teva Pharmaceuticals. 

Bipolar Disorders Section Editor Joseph F. Goldberg, MD, explains the utility and limitations of pharmacogenetics in the treatment of bipolar disorders.

Bipolar Disorders Section Editor Joseph F. Goldberg, MD, explains the concept of polarity-proneness and why clinicians should assess it when treating patients with bipolar disorder.